In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for In 2023, the FDA deemed 19 peptide drugs too unsafe to be dispensed by compounding pharmacies, which mix components of approved drugs to create bespoke medication for people who have trouble taking RFK Jr. promotes peptides. Now the FDA weighs easing limits on the unproven chemicals FDA takes first step in possible reversal of ban on some peptides The Washington Post